[Methods of detection and prognostic significance of genetic material increase of the short arm of chromosome 2 and a deletion of the short arm of chromosome 1 in patients with neuroblastoma]

Autor: Ae, Druĭ, G.A. Tsaur, Ev, Shorikov, Am, Popov, Om, Plekhanova, Sn, Typonogov, Li, Savel Ev, Sv, Tsvirenko, Lg, Fechina

Publikováno v: Europe PubMed Central

MYCN gene amplification and 1p deletion in neuroblastoma patients are associated with poor prognosis and commonly used for patient's stratification into risk groups. MYCN copy number and 1p deletion status were analyzed with multiplex ligase-dependen

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::7ce4b27dddf04f09f0e0fd0a0cae5337
https://pubmed.ncbi.nlm.nih.gov/24260886

[Minimal residual disease monitoring by flow cytometry in children with acute lymphoblastic leukemia]

Autor: Am, Popov, Verzhbitskaia TIu, Ga, Tsaur, Egor Shorikov, Li, Savel Ev, Sv, Tsvirenko, Lg, Fechina

Publikováno v: Europe PubMed Central

The cells that have avoided the action of antitumor drugs may be retained after remission achievement during induction therapy and consolidation. A combination of these cells is given the name minimal residual disease (MRD). Multicolor flow cytometry

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::b22c8dcdf42a50374eb0230fc59953b4
http://europepmc.org/abstract/med/20886718

[The TH, ELAVL4 and GD2 gene expression as diagnostic markers of bone marrow lesions in patients with neuroblastoma]

Autor: Ae, Druĭ, G.A. Tsaur, Am, Popov, Sn, Tuponogov, Ev, Shorikov, Sv, Tsvirenko, Li, Savel Ev, Lg, Fechina

Publikováno v: Europe PubMed Central

The bone marrow (BM) TH, ELAVL4 and GD2 genes expression was evaluated in 331 samples from 57 different stage neuroblastoma (NB) patients, 26 BM samples from patients without NB and samples from 2 NB cell lines (IMR-32, Kelly) by real-time PCR. BM sa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::ce8bc47cc006e93d62980657de92508f
http://europepmc.org/abstract/med/23607207

Suppressed miR-128-3p combined with TERT overexpression predicts dismal outcomes for neuroblastoma.

Autor: Druy AE; Laboratory of Molecular Oncology, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation.; Laboratory of the Cellular Therapy of Oncohematological Disorders, Research Institute of Medical Cell Technologies, Yekaterinburg, Russian Federation., Tsaur GA; Laboratory of the Cellular Therapy of Oncohematological Disorders, Research Institute of Medical Cell Technologies, Yekaterinburg, Russian Federation.; Pediatric Oncology and Hematology Center, Regional Children's Hospital, Yekaterinburg, Russian Federation.; Chair of Laboratory Medicine, Ural State Medical University, Yekaterinburg, Russian Federation., Shorikov EV; PET-Technology Center of Nuclear Medicine, Yekaterinburg, Russian Federation., Tytgat GAM; Princess Máxima Centre for Pediatric Oncology (PMC), Utrecht, The Netherlands., Fechina LG; Laboratory of the Cellular Therapy of Oncohematological Disorders, Research Institute of Medical Cell Technologies, Yekaterinburg, Russian Federation.; Pediatric Oncology and Hematology Center, Regional Children's Hospital, Yekaterinburg, Russian Federation.

Publikováno v: Cancer biomarkers : section A of Disease markers [Cancer Biomark] 2022; Vol. 34 (4), pp. 661-671.

The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia: literature review and own experience.

Autor: Dyakonova YY; Dmitry Rogachev National Research Center for Pediatric Hematology, Oncology, and Immunology, Moscow, Russia., Bydanov OI; Dmitry Rogachev National Research Center for Pediatric Hematology, Oncology, and Immunology, Moscow, Russia.; Республиканский Republican Scientific and Practical Center for Pediatric Oncology, Hematology, and Immunology, Minsk, Republic of Belarus., Popov AM; Dmitry Rogachev National Research Center for Pediatric Hematology, Oncology, and Immunology, Moscow, Russia., Olshanskaya YV; Dmitry Rogachev National Research Center for Pediatric Hematology, Oncology, and Immunology, Moscow, Russia., Boichenko EG; СПбГУЗ «Children City Hospital №1, Saint-Petersburg, Russia., Aleynikova OV; Республиканский Republican Scientific and Practical Center for Pediatric Oncology, Hematology, and Immunology, Minsk, Republic of Belarus., Maschan MA; Dmitry Rogachev National Research Center for Pediatric Hematology, Oncology, and Immunology, Moscow, Russia., Shelikhova LN; Dmitry Rogachev National Research Center for Pediatric Hematology, Oncology, and Immunology, Moscow, Russia., Litvinov DV; Dmitry Rogachev National Research Center for Pediatric Hematology, Oncology, and Immunology, Moscow, Russia., Khachatryan LA; Dmitry Rogachev National Research Center for Pediatric Hematology, Oncology, and Immunology, Moscow, Russia., Ponomareva NI; Russian Children Clinical Hospital, Moscow, Russia., Fechina LG; Regional Children Clinical Hospital №1, Ekaterinburg, Russia., Novichkova GA; Dmitry Rogachev National Research Center for Pediatric Hematology, Oncology, and Immunology, Moscow, Russia., Pashanov ED; Dmitry Rogachev National Research Center for Pediatric Hematology, Oncology, and Immunology, Moscow, Russia., Karachunskiy AI; Dmitry Rogachev National Research Center for Pediatric Hematology, Oncology, and Immunology, Moscow, Russia.

Publikováno v: Terapevticheskii arkhiv [Ter Arkh] 2018 Aug 17; Vol. 90 (7), pp. 38-50.